跳至主要内容
临床试验/ISRCTN63614165
ISRCTN63614165进行中(未招募)4 期

Effectiveness, cost effectiveness and safety of gabapentin versus placebo as an adjunct to multimodal pain regimens in surgical patients: A placebo controlled randomised controlled trial with blinding (The GAP study)

niversity Hospitals Bristol NHS Foundation Trust0 个研究点目标入组 1,196 人开始时间: 2017年6月5日最近更新:
适应症

试验速览

阶段
4 期
状态
进行中(未招募)
发起方
入组人数
1,196

研究概览

简要总结

2020 Protocol article in https://pubmed.ncbi.nlm.nih.gov/33444208/ protocol (added 15/01/2021)

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Current inclusion criteria as of 18/01/2019:
  • 1. Over 18 years of age
  • 2. Undergoing non-emergency surgery:
  • 2.1. Cardiac (surgery on the heart and great vessels carried out via midline sternotomy)
  • 2.2. Thoracic surgery (open or minimal access surgery on the lungs and surrounding tissues)
  • 2.3. Abdominal (open or minimal access surgery within the abdominal cavity)
  • 3. Expected to stay in hospital at least until day 2 after surgery (day 0 is day of surgery)
  • 4. Expected to be able to swallow during the time of the study intervention
  • Previous inclusion criteria:
  • 1. Over 18 years of age
  • 2. Undergoing non-emergency surgery:
  • 2.1. Cardiac (surgery on the heart and great vessels carried out via midline sternotomy)
  • 2.2. Thoracic surgery (surgery on the lungs and surrounding tissues)
  • 2.3. Abdominal (open or laparoscopic surgery within the abdominal cavity)

排除标准

  • Current exclusion criteria as of 18/01/2019:
  • 1. Taking anti-epileptic medication(s)
  • 2. Allergy to gabapentin
  • 3. Already taking gabapentin or gabapentanoids
  • 4. Rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose galactose malabsorption
  • 5. Planned epidural analgesia
  • 6. Intended use of any gabapentanoids in the peri-operative analgesic protocol other than the study medication (this includes but is not restricted to: pregabalin, enacarbil gabapentin, 4-methylpregabalin and phenibut)
  • 7. Known renal impairment (for such patients, estimated glomerular filtration rate (eGFR)
  • 8. Weight <50kg
  • 9. Inability to provide written informed consent to participate in the trial
  • 10. Unwilling to participate in follow-up
  • 11. Prisoners
  • 12. Enrolled in another clinical trial and: a) the patient is currently taking an investigational medicinal product as part of the other trial; or b) co-enrolment is not permitted by the other trial; or c) co-enrolment would be burdensome for the patient
  • Previous exclusion criteria:
  • 1. Expected to have a minimum length of hospital stay of less than 2 days
  • 2. Taking anti-epileptic medication(s)
  • 3. Allergy to gabapentin
  • 4. Planned epidural analgesia
  • 5. Intended use of any gabapentanoids in the peri-operative analgesic protocol other than the study medication (this includes but is not restricted to: pregabalin, enacarbil gabapentin, 4-methylpregabalin and phenibut)
  • 6. Known renal impairment (for such patients, estimated glomerular filtration rate (eGFR) <30ml/min/1.732)
  • 7. Weight <50kg
  • 8. Inability to provide written informed consent to participate in the trial
  • 9. Unwilling to participate in follow-up
  • 10. Prisoners
  • 11. Already taking gabapentin or gabapentanoids
  • 12. Rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose galactose malabsorption
  • 13. Currently taking an investigational medicinal product as part of another clinical trial

研究者

发起方
niversity Hospitals Bristol NHS Foundation Trust

相似试验